Drugs / FS VH S/D 500 s-apr
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00576420 | Dec 2007 → Nov 2008 | — | Baxter Healthcare Corporation | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FS VH S/D 500 s-apr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00576420 ↗ |
| Known as | TISSEEL | “The overall objective of this prospective, randomized, controlled, subject-blinded, multicenter phase 2 study was to evaluate the efficacy and safety of a fibrin sealant...” PMID 21514114 ↗ Apr 2011 |
| Modality | Protein / enzyme biologic | “a fibrin sealant containing 500 IU/mL thrombin and synthetic aprotinin” PMID 21514114 ↗ Apr 2011 |